192 related articles for article (PubMed ID: 30735257)
1. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease.
Shivaji UN; Sharratt CL; Thomas T; Smith SCL; Iacucci M; Moran GW; Ghosh S; Bhala N
Aliment Pharmacol Ther; 2019 Mar; 49(6):664-680. PubMed ID: 30735257
[TBL] [Abstract][Full Text] [Related]
2. A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease.
Mosli MH; Al-Harbi O; Feagan BG; Almadi MA
Saudi J Gastroenterol; 2015; 21(4):185-97. PubMed ID: 26228361
[TBL] [Abstract][Full Text] [Related]
3. Infections in inflammatory bowel disease patients on immunomodulator and biologic therapy are not associated with high serum drug levels.
Gazelakis K; Chu I; Martin C; Sparrow MP
Intern Med J; 2024 Jan; 54(1):139-148. PubMed ID: 37151186
[TBL] [Abstract][Full Text] [Related]
4. Safety of Biologic and Small Molecule Therapy for Inflammatory Bowel Disease Among Solid Organ Transplant Recipients: Systematic Review and Meta-Analysis.
Taneja V; Anand RS; El-Dallal M; Dong J; Desai N; Taneja I; Feuerstein JD
Inflamm Bowel Dis; 2024 Apr; 30(4):585-593. PubMed ID: 37300512
[TBL] [Abstract][Full Text] [Related]
5. Physiologically-Based Pharmacokinetic Modeling of Anti-Tumor Necrosis Factor Agents for Inflammatory Bowel Disease Patients to Predict the Withdrawal Time in Pregnancy and Vaccine Time in Infants.
Chen J; Lin R; Guo G; Wu W; Ke M; Ke C; Huang P; Lin C
Clin Pharmacol Ther; 2023 Dec; 114(6):1254-1263. PubMed ID: 37620249
[TBL] [Abstract][Full Text] [Related]
6. Prior Antibodies to Infliximab or Adalimumab Are Related to Immunogenicity to Vedolizumab in Patients With Inflammatory Bowel Disease.
Papamichael K; Vande Casteele N; Abraham BP; Ritter T; Jain A; Cheifetz AS
Clin Gastroenterol Hepatol; 2023 Oct; 21(11):2978-2980.e2. PubMed ID: 36372372
[No Abstract] [Full Text] [Related]
7. Anti-tumour necrosis factor-induced skin rashes in inflammatory bowel disease: a systematic review and evidence-based management algorithm.
Au M; Heddle G; Young E; Ryan E; Graf S; Tee D; Philpott H
Intern Med J; 2023 Oct; 53(10):1854-1865. PubMed ID: 35760771
[TBL] [Abstract][Full Text] [Related]
8. Infliximab-Related Infusion Reactions: Systematic Review.
Lichtenstein L; Ron Y; Kivity S; Ben-Horin S; Israeli E; Fraser GM; Dotan I; Chowers Y; Confino-Cohen R; Weiss B
J Crohns Colitis; 2015 Sep; 9(9):806-15. PubMed ID: 26092578
[TBL] [Abstract][Full Text] [Related]
9. Persistent Constitutional Symptoms and Cholestasis During Anti-TNF Therapy as a Harbinger of a Surprising Condition.
Fonseca Chebli JM; Akkari Evangelista RK; Chebli LA
Gastroenterology; 2024 Feb; 166(2):e1-e4. PubMed ID: 37490972
[No Abstract] [Full Text] [Related]
10. A review of ocular adverse events of biological anti-TNF drugs.
Nicolela Susanna F; Pavesio C
J Ophthalmic Inflamm Infect; 2020 Apr; 10(1):11. PubMed ID: 32337619
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab for treatment of very early onset inflammatory bowel disease.
Xie Y; Liu LL; Jiang Y; Tang ZZ; Sun GY; Hou XL
Chin Med J (Engl); 2019 Dec; 132(23):2889-2890. PubMed ID: 31856064
[No Abstract] [Full Text] [Related]
12. Clinical use of anti-TNF therapy and increased risk of infections.
Ali T; Kaitha S; Mahmood S; Ftesi A; Stone J; Bronze MS
Drug Healthc Patient Saf; 2013; 5():79-99. PubMed ID: 23569399
[TBL] [Abstract][Full Text] [Related]
13. Comments on: Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children.
Zapata-Cobo P; Salvador-Matín S; Velasco M; Palomino LM; Clemente S; Segarra O; Moreno-Álvarez A; Fernández-Lorenzo A; Pérez-Moneo B; Montraveta M; Sánchez C; Tolín M; Loverdos I; Fobelo MJ; Navas-López VM; Magallares L; García-Romero R; Sánchez-Hernández JG; Rodríguez A; Bossacoma F; Balboa MJ; Salcedo E; Sanjurjo-Sáez M; López-Fernández LA
Pharmacol Res; 2023 Oct; 196():106938. PubMed ID: 37748560
[No Abstract] [Full Text] [Related]
14. Anti-IL23 in inflammatory bowel disease patients with dermatological indication: The shared gastroenterological-dermatological clinic experience.
Ribaldone DG; Palumbo A; Susca S; Merli M; Dapavo P; Venero M
Dig Liver Dis; 2024 Jan; 56(1):220-222. PubMed ID: 38016896
[No Abstract] [Full Text] [Related]
15. Adverse events in IBD therapy: the 2018 update.
Quezada SM; McLean LP; Cross RK
Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1183-1191. PubMed ID: 30791788
[TBL] [Abstract][Full Text] [Related]
16. Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases.
Holmer A; Singh S
Expert Rev Clin Immunol; 2019 Sep; 15(9):969-979. PubMed ID: 31322018
[No Abstract] [Full Text] [Related]
17. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
Aardoom MA; Veereman G; de Ridder L
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
[TBL] [Abstract][Full Text] [Related]
18. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
[TBL] [Abstract][Full Text] [Related]
19. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.
Lamb CA; Kennedy NA; Raine T; Hendy PA; Smith PJ; Limdi JK; Hayee B; Lomer MCE; Parkes GC; Selinger C; Barrett KJ; Davies RJ; Bennett C; Gittens S; Dunlop MG; Faiz O; Fraser A; Garrick V; Johnston PD; Parkes M; Sanderson J; Terry H; ; Gaya DR; Iqbal TH; Taylor SA; Smith M; Brookes M; Hansen R; Hawthorne AB
Gut; 2019 Dec; 68(Suppl 3):s1-s106. PubMed ID: 31562236
[TBL] [Abstract][Full Text] [Related]
20. First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician.
Chang S; Hudesman D
Curr Gastroenterol Rep; 2020 Jan; 22(2):7. PubMed ID: 32002688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
